196 results match your criteria: "Center for Pain Relief[Affiliation]"
Pain Pract
November 2016
St. Luke's Neurosurgical Associates, St. Luke's University Health Network, Bethlehem, Pennsylvania, U.S.A.
Intrathecal drug delivery is an effective treatment option for patients with severe chronic pain who have not obtained adequate analgesia from more conservative therapies (eg, physical therapy, systemic opioids, nonsteroidal anti-inflammatory drugs, antidepressants, and anticonvulsants). This review focuses on, but is not limited to, the 2 agents currently approved by the U.S.
View Article and Find Full Text PDFNeuromodulation
February 2016
Fundacion Cardiovascular de Colombia, Bucaramanga Santander, Colombia.
Objective: This longitudinal, clinical outcome study was a multicenter, prospective, observational, registry with a 24-month assessment of patients implanted with spinal cord stimulation (SCS) systems for the management of chronic pain of the trunk and/or limbs.
Methods: On informed consent and institutional review board approval, 614 patients from 39 sites were enrolled within 30 days following permanent SCS system implantation. Medication usage, patient-reported pain relief (PRP), categorical ratings of pain relief, pain disability index scores (PDI), quality of life (QoL), and patient satisfaction were assessed at enrollment, 3-, 6-, 12-, 18-, and 24-month postimplant.
Curr Neuropharmacol
February 2017
Center for Pain Relief, Charleston, WV, USA. United States.
Background: Intrathecal drug delivery has undergone a revitalization following a better understanding of this delivery route and its pharmacokinetics. Driven by patient safety and outcomes, clinicians are motivated to rethink the traditional spinal infusion pump patient selection criteria and indications. We review the current understanding of the pharmacology of commonly employed intrathecal agents and the clinical relevance.
View Article and Find Full Text PDFMayo Clin Proc
February 2016
Department of Anesthesiology, University Hospitals Case Medical Center, Cleveland, OH.
Chronic pain represents one of the most important public health problems in terms of both the number of patients afflicted and health care costs. Most patients with chronic pain are treated with medications as the mainstay of therapy, and yet most medically treated patients continue to report ongoing pain. Additionally, adverse effects from pain medications represent a major challenge for clinicians and patients.
View Article and Find Full Text PDFNeuromodulation
January 2016
Cleveland Clinic Foundation, Pain Management, Cleveland, OH, USA.
Introduction: Currently available central nervous system treatment strategies are often insufficient in management of peripheral neuropathic pain, prompting a resurgence of neuromodulation focused on peripheral pain. A new peripheral nerve stimulation device was investigated in a prospective, randomized, double blind, crossover study, looking specifically at efficacy and safety, with Food and Drug Administration oversight.
Methods: Prospective, multicenter, randomized, double-blind, partial crossover study to assess safety and efficacy.
Neuromodulation
December 2015
Neuromodulation Service, Department of Anesthesia and Perioperative Care, University of California at San Francisco, UCSF Pain Management Center, San Francisco, CA, USA.
Neuromodulation
December 2015
Center for Pain Relief, Inc., Charleston, WV, USA.
Med Clin North Am
January 2016
Anesthesiology and Pain Medicine, UW Center for Pain Relief, University of Washington, 4225 Roosevelt Way Northeast, Box 354693, Seattle, WA 98105, USA.
Most patients with chronic pain receive multimodal treatment. There is scant literature to guide us, but when approaching combination pharmacotherapy, the practitioner and patient must weigh the benefits with the side effects; many medications have modest effect yet carry significant side effects that can be additive. Chronic pain often leads to depression, anxiety, and deconditioning, which are targets for treatment.
View Article and Find Full Text PDFHand Clin
February 2016
Center for Pain Relief, Charleston, WV 25304, USA.
Upper extremity neuropathic pain states greatly impact patient functionality and quality of life, despite appropriate surgical intervention. This article focuses on the advanced therapies that may improve pain care, including advanced treatment strategies that are available. The article also surveys therapies on the immediate horizon, such as spinal cord stimulation, peripheral nerve stimulation, and dorsal root ganglion spinal cord stimulation.
View Article and Find Full Text PDFNeuromodulation
January 2016
Rush University Medical Center, Chicago, IL, USA.
Objectives: Surgical site infections (SSIs) are associated with significant healthcare costs and morbidity. Limited research exists specific to the prevention of spinal cord stimulation (SCS) SSIs. The objectives of this international survey were to examine current infection control practices for SCS trials and implants and to compare reported responses with evidence-based recommendations.
View Article and Find Full Text PDFExpert Rev Clin Pharmacol
April 2016
a 1 CEO Center for pain relief, Charleston, WV, USA.
Medication selection for neuropathic pain follows a path of evidence, with respect to appreciating the patient's entry into the pain care algorithm. As we decide how to approach neuropathic pain, the considerations for intrathecal therapy medication selection are bound by catheter location, region of pain, and patient selection, to name a few. Future research and the 2016 polyanalgesic consensus conference may further provide patient care through a mindful eye on the improvement of patient safety and a reduction of the societal needs of opioids.
View Article and Find Full Text PDFPain Physician
October 2015
Center for Pain Relief, Inc., Charleston, WV; Ethos, Research & Development, Fairfield, OH.
Pain Med
October 2015
Holy Cross Hospital, Fort Lauderdale, FL.
Phys Med Rehabil Clin N Am
May 2015
Division of Pain Medicine, Department of Anesthesiology and Pain Medicine, UW Center for Pain Relief, University of Washington, 1959 Northeast Pacific Street, Box 356540, Seattle, WA 98195, USA; Division of General Internal Medicine, Department of Medicine, UW Center for Pain Relief, University of Washington, 1959 Northeast Pacific Street, Box 356540, Seattle, WA 98195, USA. Electronic address:
Evidence of nonopioid analgesic effectiveness exceeds that for long-term opioids in chronic noncancer pain (CNCP), most with lower risk. Non-drug therapies such as cognitive behavioral therapy and physical activation are safer and also effective. Nonsteroidal antiinflammatory drugs are useful for inflammatory and nociceptive pain, share renal and variable gastrointestinal, bleeding and cardiovascular side effects.
View Article and Find Full Text PDFReg Anesth Pain Med
April 2016
From the *Center for Pain Medicine, Western Reserve Hospital, Cuyahoga Falls, OH; †Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL; ‡Pain Diagnostics and Interventional Care, Pittsburgh, PA; §Rush Medical Center, Chicago, IL; ∥Department of Anesthesiology, Critical Care, and Pain Management, Valencia University School of Medicine, General University Hospital, Valencia, Spain; #The Center for Pain Relief, Charleston, WV; **Carolinas Pain Institute, Winston Salem, NC; and ††Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN.
Interventional spine and pain procedures cover a far broader spectrum than those for regional anesthesia, reflecting diverse targets and goals. When surveyed, interventional pain and spine physicians attending the American Society of Regional Anesthesia and Pain Medicine (ASRA) 11th Annual Pain Medicine Meeting exhorted that existing ASRA guidelines for regional anesthesia in patients on antiplatelet and anticoagulant medications were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors necessitated separate guidelines for pain and spine procedures.
View Article and Find Full Text PDFExpert Rev Med Devices
July 2015
Center for Pain Relief, Inc., 400 Court Street, Charleston, WV 25301, USA.
In recent years, software development has been key to the next generation of neuromodulation devices. In this review, we will describe the new strategies for electrical waveform delivery for spinal cord stimulation. A systematic literature review was performed using bibliographic databases, limited to the English language and human data, between 2010 and 2014.
View Article and Find Full Text PDFPain Physician
October 2015
Center for Pain Relief, Inc, Charleston, WV; Ethos Research & Development, Fairfield, OH.
Blood testing is quickly becoming a useful laboratory tool for opioid prescribers who wish to document and assess patient tolerance, more objectively monitor patient safety, and evaluate patient compliance using information that is not available with traditional urine drug testing (UDT). Blood testing does not need to be performed as frequently as UDT but provides extremely valuable information which can be used to more accurately evaluate patient compliance and assist with interpreting blood toxicology results commonly used in impairment or overdose cases. This narrative review presents the current evidence supporting the use of blood testing within the chronic pain management setting.
View Article and Find Full Text PDFNeuromodulation
July 2015
Center for Pain Relief, Charleston, WV, USA.
Introduction: Intrathecal drug delivery is a well-defined strategy to treat malignant and nonmalignant pain. Ziconotide is a well-studied intrathecal medicine option that has many attractive qualities, as it is non-granulomagenic, overdose or underdose is not associated with cardiopulmonary compromise or death, and is a non-opoid analgesic. However, it has had slow adoption into pain care algorithms because it has been historically plagued with the connotation of having a narrow therapeutic window and a low sustainability rate.
View Article and Find Full Text PDFPain Med
March 2015
President and CEO, The Center for Pain Relief, Inc; Clinical Professor of Anesthesiology, West Virginia University School of Medicine, Charleston, West Virginia, USA.
Pain Med
January 2015
Center for Pain Relief, Inc., Charleston, West Virginia, USA.
Neuromodulation
December 2014
The Center for Pain Relief, Charleston, WV, USA.
Neuromodulation
October 2014
Center for Pain Relief, Charleston, WV, USA.
Introduction: The use of spinal cord stimulation (SCS) is well established in the treatment of neuropathic pain. This procedure has been approved in the United States for neuropathic pain of the trunk and limbs from various conditions. International use is variable based on governmental policy.
View Article and Find Full Text PDFJ Pediatr Psychol
October 2015
Children's Healthcare of Atlanta, Center for Pain Relief, and Emory University School of Medicine.
Objective: Fear of pain and pain catastrophizing are prominent risk factors for pediatric chronic pain-related maladjustment. Although resilience has largely been ignored in the pediatric pain literature, prior research suggests that optimism might benefit youth and can be learned. We applied an adult chronic pain risk-resilience model to examine the interplay of risk factors and optimism on functioning outcomes in youth with chronic pain.
View Article and Find Full Text PDFNeuromodulation
June 2015
University of Illinois-Chicago, Chicago, IL, USA.
Objective: In this study, we analyze device- and procedure-related adverse events (AEs) from a recent prospective, multicenter, double-blinded controlled study that utilized peripheral nerve stimulation (PNS) of occipital nerves for management of chronic migraine.
Methods: PNS device characteristics (lead length and spacing), surgical techniques including lead orientation (parallel or perpendicular to the nerve), and implantable pulse generator (IPG) placement (upper buttock, abdomen, infraclavicular, or lower axilla) in 157 patients were analyzed to identify any relationship with the AE incidence rate. Number of prior PNS implants performed (NPPIP) by the implanter and its relationship with different AE categories (hardware-related, biological, and stimulation-related events) and frequently observed device/procedure-related AEs (lead migration/fracture/breakage, persistent pain at the lead/IPG location, unintended/undesirable changes in stimulation, infection) were also evaluated.
Introduction: The International Neuromodulation Society (INS) has determined that there is a need to provide an expert consensus that defines the appropriate use of neuromodulation technologies for appropriate patients. The Neuromodulation Appropriateness Consensus Committee (NACC) was formed to give guidance to current practice and insight into future developments.
Methods: The INS executive board selected members of the international scientific community to analyze scientific evidence for current and future innovations and to use clinical experience to fill in any gaps in information.